Vedolizumab Crohn’s Disease: Early vs. Late Treatment
- A recent phase 4,investigator-initiated cohort study involving 260 patients with moderate to severe crohn's disease demonstrates that vedolizumab treatment is more effective and safer when initiated earlier in...
- All participants received intravenous vedolizumab at a dosage of 300 mg at weeks 0, 2, and 6, followed by maintenance infusions every eight weeks for up to 52...
- The primary endpoint - achieving both clinical and endoscopic remission at weeks 26 and 52 - was met by 21.4% (27 of 86) of patients in the early...
Vedolizumab Shows greater Efficacy and Safety in Early-Stage CrohnS Disease
Table of Contents
Published November 13,2025
Study Highlights Early Intervention Benefits
A recent phase 4,investigator-initiated cohort study involving 260 patients with moderate to severe crohn’s disease demonstrates that vedolizumab treatment is more effective and safer when initiated earlier in the disease course. The study, conducted over 52 weeks, compared outcomes in patients with early Crohn’s disease (diagnosed within two years and treatment-naive) versus those with late-stage disease (diagnosed over two years ago and previously treated with corticosteroids, immunomodulators, and anti-TNF agents).
Study Design and Treatment Protocol
All participants received intravenous vedolizumab at a dosage of 300 mg at weeks 0, 2, and 6, followed by maintenance infusions every eight weeks for up to 52 weeks. Patients who did not achieve a clinical decrease of at least 70 points in their Crohn’s Disease Activity Index (CDAI) by week 6 received an additional 300 mg infusion at week 10. Colonoscopies with biopsies were performed at the beginning of the study,at week 26,and at week 52 to assess endoscopic remission.
Remission Rates Significantly Higher in Early Disease
The primary endpoint – achieving both clinical and endoscopic remission at weeks 26 and 52 - was met by 21.4% (27 of 86) of patients in the early disease group, compared to only 8.6% (15 of 174) in the late disease group. This represents a considerable difference of 12.8%, suggesting a meaningful benefit to initiating vedolizumab treatment quickly after diagnosis.
Safety Profile Favors Early Treatment
The incidence of serious adverse events was markedly lower in the early disease group (3.5%) compared to the late disease group (26.4%). Common serious adverse events included infections (1.2% vs 7.5%), surgery (0% vs 4.6%), intestinal obstruction (0% vs 2.3%), Crohn’s disease exacerbation (1.2% vs 3.4%), and malignancy (0% vs 1.7%). These findings reinforce the importance of early intervention to potentially minimize treatment-related complications.